Glioblastoma radiosensitization by pimozide

Glioblastoma (GBM) is the most common form of malignant brain tumor corresponding to approximately 20,000 new cases in the US per year (1). While the best available treatment involves surgery followed by the combination of radiotherapy and temozolomide (2), the survival of the vast majority of patients with GBM remains less than 2 years after diagnosis. Accordingly, considerable research has continued into the development of more effective GBM therapy. At the fundamental and preclinical levels such research has focused on developing experimental models that accurately reflect GBM biology, defining the molecules mediating GBM cell survival and treatment resistance and identifying drugs suitable for targeting those molecules within the constraints of CNS physiology. In the recent article by Lee et al. (3), each of these topics has been addressed in an attempt to suggest a novel, more effective GBM treatment strategy.